InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is making changes in its scientific management team. The company announced that Michael Palfreyman, PhD, and Brett Greene, both of whom joined Cybin as part of the acquisition of Adelia Therapeutics, will be moving into advisory roles; the company noted that Alex Nivorozhkin,…